Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
It is a recombinant nanoparticle protein-based vaccine
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Subscribe To Our Newsletter & Stay Updated